Efficacy and safety of valganciclovir in liver-transplanted children infected with Epstein-Barr virus

Liver Transplantation

Volumn 14, Issue 8, 2008, Pages 1185-1193

  Hierro, Loreto ^a   Díez Dorado, Ruth ^a   Díaz, Carmen ^a   De la Vega, Angela ^a   Frauca, Esteban ^a   Camarena, Carmen ^a   Muñoz Bartolo, Gema ^a   de Zárate, Ana González ^a   Santamaría, Manuel López ^a   Jara, Paloma ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTINEOPLASTIC AGENT; AZATHIOPRINE; BASILIXIMAB; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DOXORUBICIN; GANCICLOVIR; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; STEROID; TACROLIMUS; VALGANCICLOVIR; VINCRISTINE; VIRUS DNA;

ARTICLE; BURKITT LYMPHOMA; CHILD; CHOLANGITIS; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DNA DETERMINATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EPSTEIN BARR VIRUS; GASTROINTESTINAL INFECTION; HUMAN; IMMUNE DEFICIENCY; INFECTION; JEJUNUM BIOPSY; LIVER BIOPSY; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LONG TERM CARE; LYMPHOCYTOMA; LYMPHOPROLIFERATIVE DISEASE; MONOTHERAPY; MUCOSA INFLAMMATION; NEUTROPENIA; PANCYTOPENIA; PNEUMONIA; PRIORITY JOURNAL; RECURRENT VIRUS INFECTION; SALIVARY GLAND DISEASE; SHORT COURSE THERAPY; SIDE EFFECT; SYMPTOMATOLOGY; THROMBOCYTOPENIA; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VIRUS INFECTION; VIRUS LOAD;

ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; GANCICLOVIR; GRAFT REJECTION; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOSUPPRESSION; INFANT; KIDNEY FUNCTION TESTS; LIVER DISEASES; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; RESPIRATORY TRACT INFECTIONS; VIRUS REPLICATION;

EID: 49649097948     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21498     Document Type: Article

References (23)

1. Kelly D, Jara P, Rodeck B, Lykavieris P, Burdelski M, Becker M, et al. Tacrolimus and steroids versus ciclosporin microemulsion, steroids, and azathioprine in children undergoing liver transplantation: randomised European multicentre trial. Lancet 2004;364:1054-1061.
2. Smets F, Bodeus M, Goubau P, Reding R, Otte JB, Buts JP, Sokal EM. Characteristics of Epstein-Barr virus primary infection in pediatric liver transplant recipients. J Hepatol 2000;32:100-104.
3. Cohen JI. Epstein Barr virus infection. N Engl J Med 2000; 343:481-492.
4. Smets F, Sokal EM. Epstein-Barr virus-related lymphoproliferation in children after liver transplant: role of immunity, diagnosis, and management. Pediatr Transplant 2002;6:280-287.
5. Cockfield SM. Identifying the patient at risk for post-transplant lymphoproliferative disorder. Transpl Infect Dis 2001;3:70-78.
6. Jain A, Mazariegos G, Kashyap R, Kosmach-Park B, Starzl TE, Fung J, Reyes J. Pediatric liver transplantation. A single center experience spanning 20 years. Transplantation 2002;73:941-947.
7. Wallot MA, Mathot M, Janssen M, Holter T, Pau KL, Buts JP, et al. Long-term survival and late graft loss in pediatric liver transplant recipients - a 15-year single-center experience. Liver Transpl 2002;8:615-622.
8. Migliazza L, Lopez Santamaria M, Murcia J, Gamez M, Clavijo J, Camarena C, et al. Long-term survival expectancy after liver transplantation in children. J Pediatr Surg 2000;35:5-7.
9. Kogan-Liberman D, Burroughs M, Emre S, Moscona A, Shneider BL. The role of quantitative Epstein-Barr virus polymerase chain reaction and preemptive immunosuppression reduction in pediatric liver transplantation: a preliminary experience. J Pediatr Gastroenterol Nutr 2001;33:445-449.
10. Kullberg-Lindh C, Ascher H, Saalman R, Olausson M, Lindh M. Epstein-Barr viremia levels after pediatric liver transplantation as measured by real-time polymerase chain reaction. Pediatr Transplant 2006;10:83-89.
11. Scheenstra R, Verschuuren EA, de Haan A, Slooff MJ, The TH, Bijleveld CM, Verkade HJ. The value of prospective monitoring of Epstein-Barr virus DNA in blood samples of pediatric liver transplant recipients. Transpl Infect Dis 2004;6:15-22.
12. Green M, Michaels MG, Webber SA, Rowe DT, Reyes J. The management of Epstein-Barr virus associated post-transplant lymphoproliferative disorders in pediatric solid-organ recipients. Pediatr Transplant 1999;3:271-281.
13. Hurwitz M, Desai DM, Cox KL, Berquist WE, Esquivel CO, Milian MT. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation. Pediatr Transplant 2004;8:267-272.
14. Spada M, Guizzetti M, Petz W, Colledan M, Segalin A, Lucianetti A, et al. Circulating EBV-DNA in the monitoring of EBV infection in pediatric liver transplant recipients. Transplant Proc 2001;33:1835-1837.
15. Green M, Webber SA. Persistent increased Epstein-Barr virus loads after solid organ transplantation: truth and consequences? Liver Transpl 2007;13:321-322.
16. D'Antiga L, Del Rizzo M, Mengoli C, Cillo U, Guariso G, Zancan L. Sustained Epstein-Barr virus detection in paediatric liver transplantation. Insights into the occurrence of late PTLD. Liver Transpl 2007;13:343-348.
17. Lee TC, Savoldo B, Rooney CM, Heslop HE, Gee AP, Caldwell Y, et al. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatriclivertransplantrecipients.AmJTransplant2005;5: 2222-2228.
18. McDiarmid S, Jordan S, Lee G, Toyoda M, Goss JA, Vargas JH. Prevention and preemptive therapy of posttransplant lymphoproliferative disease in pediatric liver recipients. Transplantation 1998;66:1604-1611.
19. Thorley-Lawson DA, Andrew Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 2004;350:1328-1337.
20. Pescovitz MD, Rabkin J, Merion RM, Paya CV, Pirsch J, Freeman RB, et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000;44:2811-2815.
21. Lee TC, Goss JA, Rooney CM, Heslop HE, Barshes NR, Caldwell YM, et al. Quantification of a low cellular immune response to aid in identification of pediatric liver transplant recipients at high-risk for EBV infection. Clin Transplant 2006;20:689-694.
22. Opelz G, Daniel V, Naujokat C, Fickenscher H, Döhler B. Effect of cytomegalovirus prophylaxis with immunoglobulin or with antiviral drugs on post-transplant non-Hodgkin lymphoma: a multicentre retrospective analysis. Lancet Oncol 2007;8:212-218.
23. Comolo P, Basso S, Zecca M, Pagliara D, Baldanti F, Bernardo ME, et al. Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation. Am J Transplant 2007;7:1648-1655.